IL138665A0 - Peptide factor - Google Patents

Peptide factor

Info

Publication number
IL138665A0
IL138665A0 IL13866599A IL13866599A IL138665A0 IL 138665 A0 IL138665 A0 IL 138665A0 IL 13866599 A IL13866599 A IL 13866599A IL 13866599 A IL13866599 A IL 13866599A IL 138665 A0 IL138665 A0 IL 138665A0
Authority
IL
Israel
Prior art keywords
peptide factor
present
thymosin beta
oxidised thymosin
peptide
Prior art date
Application number
IL13866599A
Other languages
English (en)
Original Assignee
Univ Glasgow
Imp Cancer Res Tech
Stevenson Robert Duncan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Glasgow, Imp Cancer Res Tech, Stevenson Robert Duncan filed Critical Univ Glasgow
Publication of IL138665A0 publication Critical patent/IL138665A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
IL13866599A 1998-03-28 1999-03-29 Peptide factor IL138665A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806632.7A GB9806632D0 (en) 1998-03-28 1998-03-28 Peptide factor
PCT/GB1999/000833 WO1999049883A2 (fr) 1998-03-28 1999-03-29 Thymosine beta 4 oxydee

Publications (1)

Publication Number Publication Date
IL138665A0 true IL138665A0 (en) 2001-10-31

Family

ID=10829414

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13866599A IL138665A0 (en) 1998-03-28 1999-03-29 Peptide factor

Country Status (15)

Country Link
US (3) US6602519B1 (fr)
EP (1) EP1094833B1 (fr)
JP (1) JP2002509893A (fr)
KR (1) KR20010074461A (fr)
CN (2) CN1178695C (fr)
AT (1) ATE232396T1 (fr)
AU (1) AU766493B2 (fr)
CA (1) CA2325984A1 (fr)
DE (1) DE69905368T2 (fr)
ES (1) ES2192839T3 (fr)
GB (1) GB9806632D0 (fr)
IL (1) IL138665A0 (fr)
NZ (1) NZ507642A (fr)
WO (1) WO1999049883A2 (fr)
ZA (1) ZA200005196B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
US20070015698A1 (en) * 1998-07-30 2007-01-18 United States Of America As Represented By The Secretary Of Health Treatment of skin, and wound repair, with thymosin beta 4
US20060100156A1 (en) * 2004-10-01 2006-05-11 Regenerx Biopharmaceuticals, Inc. Cell nucleus-entering compositions
US20040067227A1 (en) * 2001-11-02 2004-04-08 Goldstein Allan L. Inhibition or reversal of skin aging by actin-sequestering peptides
ATE292473T1 (de) * 1998-07-30 2005-04-15 Us Gov Health & Human Serv Thymosin beta 4 stimuliert wundheilung
US20070191275A1 (en) * 1998-07-30 2007-08-16 Regenerx Biopharmaceuticals, Inc. Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments
ES2307662T3 (es) * 2000-10-20 2008-12-01 Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur Proteinas oxidadas y su actividad biologica y terapeutica, asi como su utilizacion en el diagnostico por medio de la inhibicion de la interaccion entre proteinas oxidadas y la cd36.
ATE452647T1 (de) 2000-11-02 2010-01-15 Regenerx Biopharmaceuticals Hemmung oder umkehrung der hautalterung durch actin-sequestrierende peptide
AU2002255736B2 (en) * 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
CN101549148A (zh) * 2001-08-29 2009-10-07 雷根内克斯生物制药有限公司 多肽在制备用于促进心内膜细胞向间质细胞转化的药物中的应用
AU2008201749B2 (en) * 2002-02-06 2010-05-13 Regenerx Biopharmaceuticals, Inc. Treatment of Infections and Other Disorders
EP1497322A4 (fr) * 2002-02-06 2006-11-08 Regenerx Biopharmaceuticals Traitement d'infections et d'autres troubles
WO2003086449A1 (fr) * 2002-04-12 2003-10-23 Yale University Effets de cicatrisation de blessure et anti-inflammatoires de la thymosine $g(b)4 lymphoide
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
CA2517154A1 (fr) * 2003-03-31 2004-10-28 Regenerx Biopharmaceuticals, Inc. Compositions et procedes d'administration de thymosine beta 4, d'analogues, d'isoformes et autres derives
WO2005027958A1 (fr) * 2003-09-19 2005-03-31 Imperial College Innovations Ltd Thymosine-beta-sulphoxyde comme immunodepresseur actif
EP1706136A4 (fr) * 2003-12-22 2009-09-16 Regenerx Biopharmaceuticals Procede de traitement ou de prevention des reponses biologiques ou immunologiques a un agent reactif chimique, biologique ou toxique
US8399609B2 (en) * 2004-03-05 2013-03-19 Regenerx Biopharmaceuticals, Inc. Treating or preventing extracellular matrix build-up
US20080248993A1 (en) * 2005-01-14 2008-10-09 Regenerx Biopharmaceuticals, Inc. Modified Beta Thymosin Peptides
CN105106931A (zh) 2005-06-17 2015-12-02 雷金纳克斯生物制药公司 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
WO2007012066A2 (fr) * 2005-07-19 2007-01-25 Grannus Biosciences Thymosine ?4 oxydee tronquee et derives de celle-ci
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
US20100247693A1 (en) * 2009-03-24 2010-09-30 Marini Jan L Cosmetic formulation to treat rosacea telangiectasia
US20110160144A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Formulations
US8580742B2 (en) * 2010-03-05 2013-11-12 N.V. Perricone Llc Topical glutathione formulations for menopausal skin
US8609604B2 (en) 2009-12-28 2013-12-17 N.V. Perricone Llc Methods of improving the appearance of aging skin
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
US9808654B2 (en) 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
CN110215513B (zh) * 2018-11-15 2022-02-22 北京诺思兰德生物技术股份有限公司 经修饰的胸腺素β4在治疗放射性肠炎方面的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US388234A (en) * 1888-08-21 Car-brake
US3998798A (en) * 1972-12-22 1976-12-21 The Trustees Of The University Of Pennsylvania Monellin, a sweet polypeptide derived from fruit of dioscoreophyllum cumminsii
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US4389343A (en) 1981-12-24 1983-06-21 Hoffmann-La Roche Inc. Immunopotentiating peptides from thymus
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
TW249754B (fr) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor

Also Published As

Publication number Publication date
KR20010074461A (ko) 2001-08-04
EP1094833A2 (fr) 2001-05-02
DE69905368T2 (de) 2003-12-18
GB9806632D0 (en) 1998-05-27
NZ507642A (en) 2003-10-31
CN1308543A (zh) 2001-08-15
CN1178695C (zh) 2004-12-08
ES2192839T3 (es) 2003-10-16
JP2002509893A (ja) 2002-04-02
US6602519B1 (en) 2003-08-05
ATE232396T1 (de) 2003-02-15
US20060229234A1 (en) 2006-10-12
WO1999049883A2 (fr) 1999-10-07
ZA200005196B (en) 2002-01-02
CA2325984A1 (fr) 1999-10-07
EP1094833B1 (fr) 2003-02-12
DE69905368D1 (en) 2003-03-20
WO1999049883A3 (fr) 2001-02-22
US20040213772A1 (en) 2004-10-28
AU766493B2 (en) 2003-10-16
AU3155399A (en) 1999-10-18
CN1644586A (zh) 2005-07-27

Similar Documents

Publication Publication Date Title
IL138665A0 (en) Peptide factor
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
NO994431L (no) Ny formulering
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
ZA968990B (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
BG103543A (en) The use of pramipexol in the treatment of the uneasy legs syndrome
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
ZA929879B (en) Compositions for the treatment of mammalian diseases.
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
AU9743698A (en) Allelic variant of human stat3
MD980129A (en) Antiherpetic remedy
AU7402600A (en) New sequence variants of the human beta1-adrenoreceptor genes and use thereof

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees